Literature DB >> 26664255

Visceral Fat Area Determined Using Bioimpedance Analysis Is Associated with Hearing Loss.

Seok Hui Kang1, Da Jung Jung2, Eun Woo Choi1, Jong Won Park1, Kyu Hyang Cho1, Kyu Yup Lee2, Jun Young Do1.   

Abstract

BACKGROUND: Visceral fat area (VFA) using bioimpedance analysis (BIA) as a simple analyzer can be used to assess VFA, which may be associated with HL. The aim of the present study was to evaluate the clinical relevance and usefulness of VFA using BIA as a predictor of HL. PATIENTS AND METHODS: In total, 18,415 patients were recruited into our study. VFAs were measured using multi-frequency BIA. VFAs were normalized by body mass index (BMI). Participants were divided into 3 tertiles based on their VFA/BMI for both sexes. For both ears of each participant, the low-frequency (Low-Freq), mid-frequency (Mid-Freq), and high-frequency (High-Freq) values were obtained calculating the pure tone averages at 0.5 and 1 kHz, 2 and 3 kHz, and 4 and 6 kHz, respectively. The average hearing threshold (AHT) was calculated as the pure tone average at the 4 frequencies (i.e., 0.5, 1, 2, and 3 kHz). HL was defined as AHT >40 dB.
RESULTS: The VFA/BMI had the greatest AUROC among VFA, BMI, and VFA/BMI in both sexes in this study. In both univariate and multivariate analyses, VFA/BMI tertiles were associated with all 4 hearing thresholds (i.e., Low-Freq, Mid-Freq, High-Freq, and AHT). The 4 hearing thresholds were positively correlated with VFA/BMI as a continuous variable. The odds ratio for HL increased as the VFA/BMI tertile increased.
CONCLUSION: VFA/BMI was associated with hearing impairment in the Asian population. The participants with high VFA/BMI should be closely monitored for hearing impairment.

Entities:  

Keywords:  Visceral fat area; bioimpedance analysis.; body mass index; hearing threshold

Mesh:

Year:  2015        PMID: 26664255      PMCID: PMC4661292          DOI: 10.7150/ijms.13184

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


Introduction

Hearing loss (HL) is one of the most common public health problems. Obesity is a well-known risk factor for HL in the general population 1-3. Obesity is associated with the development of cardiovascular disease, including cochlear vasculopathies. Body mass index (BMI) has been known as a classic obesity indicator. However, BMI cannot be used to differentiate fat from free-fat mass. The reliability of BMI as a representation of fat mass has been questioned 4. During previous studies, conflicting results regarding the association between hearing impairment and BMI have been observed 3,5,6. Fat, a constituent of body mass, is a biologically active tissue associated with the development of cardiometabolic complications. There are significant clinical and prognostic differences between subcutaneous and visceral fat tissues. Visceral fat tissue is more biologically active than subcutaneous fat tissue 7. Kim et al. showed an association between visceral fat are (VFA) using computed tomography and hearing thresholds 8. Computed tomography and magnetic resonance imaging at the umbilical level have been known as the gold standard for assessing visceral fat accumulation 9. However, these methods involve x-ray irradiation or require an expensive equipment and relatively long imaging time. Multi-frequency bioimpedance analysis (BIA) is a simple method for assessing body compositions, including VFA. BIA uses electrical current resistance and impedance to measure body compositions. In our previous study, we showed that VFA measured using BIA was significantly correlated with that acquired by the computed tomography 10. Therefore, VFA using BIA as a simple analyzer can be used to assess VFA, which may be associated with HL. The aim of the present study was to evaluate the clinical relevance and usefulness of VFA using BIA as a predictor of HL.

Methods

Study population

We identified 20,726 adults (≥40 years old) who underwent voluntary routine health checkups at Yeungnam University Hospital between June 2008 and April 2014. Data acquired during the first visit were used when patients underwent multiple examinations. Among these patients, 2,311 were excluded due to a lack of laboratory findings or BIA data. In total, 18,415 patients were recruited into our study. This study was approved by the Institutional Review Board of Yeungnam University Hospital. The board waived the need for informed consent because the patients' records and information were anonymized and de-identified prior to analysis.

Study variables

Clinical and laboratory data collected from the participants during the health examination included the following variables: age, sex, body mass index (BMI; kg/m2), VFA (cm2), systolic blood pressure (SBP; mmHg), diastolic blood pressure (DBP; mmHg), serum creatinine level (mg/dL), estimated glomerular filtration rate (eGFR; mL/min/1.73m2), fasting blood glucose level (FBG; mg/dL), total cholesterol level (mg/dL), triglyceride level (TG; mg/dL), high-density lipoprotein (HDL) cholesterol level (mg/dL), and hearing thresholds. BMI was calculated as body weight divided by height squared [body weight (kg)/height (m2)]. VFAs were measured using multi-frequency BIA (In-Body 720; Biospace, Seoul, Korea). VFAs were normalized by BMI. Participants were divided into 3 tertiles based on their VFA/BMI for both sexes: low, middle, and high tertiles. Serum creatinine levels were measured using a Hitachi Automatic Analyzer (alkaline picrate, Jaffé kinetic reaction). The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation 11. Chronic kidney disease was defined as an eGFR <60 mL/min/1.73 m2. Diabetes mellitus (DM) was defined as a self-reported history of DM diagnosis or a fasting glucose level ≥126 mg/dL. Hypertension was defined as an SBP ≥140 mmHg, DBP ≥90 mmHg, a self-reported history of hypertension or use of anti-hypertensive drugs. The hearing thresholds were measured using an automatic audiometer at 0.5, 1, 2, 3, 4, and 6 kHz. None of the participants had been receiving medication associated with ototoxicity or had ear disease (i.e., chronic otitis media). For both ears of each participant, the low-frequency (Low-Freq), mid-frequency (Mid-Freq), and high-frequency (High-Freq) values were obtained calculating the pure tone averages at 0.5 and 1 kHz, 2 and 3 kHz, and 4 and 6 kHz, respectively. In the present study, the average hearing threshold (AHT) was calculated as the pure tone average at the 4 frequencies (i.e., 0.5, 1, 2, and 3 kHz). HL was defined as AHT >40 dB.

Statistical analyses

Data were analyzed using SPSS version 21 (SPSS, Chicago, IL, USA). Categorical variables were expressed as numbers and percentages. Continuous variables were expressed as mean ± standard deviation or standard error. The Pearson's χ2 test or Fisher's exact test was used to analyze categorical variables. For continuous variables, means were compared using one-way analysis of variance. Linear regression analysis was performed to assess the independent predictors of AHT. Logistic regression analyses were used to estimate odds ratios and 95% confidence intervals (CI) to determine the relationship between VFA/BMI tertiles and HL. Multivariate analysis was adjusted for age, DM, HTN, and CKD. Variance inflation factor (VIF) was used to identify multicollinearity for the multivariate linear regression model. VIF greater than 10 was not accepted. Discrimination, the ability of the model to differentiate between participants with and without HL, was examined using the area under the receiver operating characteristic curve (AUROC). AUROC analysis was also performed to calculate cutoff values, sensitivity, and specificity. The cutoff risk point was defined as the highest sensitivity (100 - specificity) value in the AUROC. The statistical significance between AUROC values was calculated by the DeLong method. The AUROC was calculated using MedCalc version 11.6.1.0 (Medcalc, Mariakerke, Belgium). The level of statistical significance was set at P <0.05.

Results

Clinical characteristics of the participants

There were 3,410, 3,406, and 3,401 men and 2,733, 2,735, and 2,730 women in the low, middle, and high VFA/BMI tertiles, respectively. The mean VFA/BMI in the low, middle, and high tertiles were 3.37 ± 0.48 (0.23-3.89), 4.19 ± 0.16 (3.90-4.46), and 4.95 ± 0.41 (4.47-7.02), respectively, in men and 3.12 ± 0.38 (1.20-3.59), 3.92 ± 0.19 (3.60-4.24), and 4.78 ± 0.41 (4.25-6.64), respectively, in women (Table 1). In both sexes, the portions of participants with DM, hypertension, and chronic kidney disease increased with increasing VFA/BMI tertiles. Furthermore, age, BMI, and TG levels increased with increasing VFA/BMI tertiles in both sexes.
Table 1

Clinical characteristics of the participants according to visceral fat are/body mass index tertiles.

MenWomen
LowMiddleHighPLowMiddleHighP
Age (years)48.6 ± 6.752.5 ± 6.761.2 ± 9.3<0.00146.7 ± 5.353.2 ± 6.364.3 ± 8.3<0.001
BMI (kg/m2)23.6 ± 2.625.0 ± 2.625.2 ± 3.0<0.00121.7 ± 2.223.6 ± 2.624.9 ± 3.2<0.001
VFA (cm2)79.7 ± 15.7104.7 ± 11.8124.6 ± 17.3<0.00168.3 ± 12.792.8 ± 11.6119.0 ± 18.6<0.001
Diabetes mellitus215 (6.3%)372 (10.9%)604 (17.8%)<0.00153 (1.9%)156 (5.7%)405 (14.8%)<0.001
Hypertension499 (14.6%)738 (21.7%)1042 (30.6%)<0.001158 (5.8%)357 (13.1%)758 (27.8%)<0.001
eGFR (mL/min/1.73m2)67.8 ± 12.066.8 ± 11.863.7 ± 15.1<0.00198.7 ± 25.395.9 ± 25.789.0 ± 30.5<0.001
CKD (%)821 (24.0%)984 (28.9%)1335 (39.4%)<0.00120 (0.7%)36 (1.3%)104 (3.8%)<0.001
FBG (mg/dL)93.6 ± 21.497.5 ± 23.7101.4 ± 28.1<0.00188.3 ± 15.091.6 ± 16.698.6 ± 24.9<0.001
TC (mg/dL)197.8 ± 35.1203.6 ± 34.9202.8 ± 40.1<0.001188.3 ± 32.4204.2 ± 35.3211.7 ± 38.4<0.001
TG (mg/dL)134.4 ± 99.7161.7 ± 112.6156.8 ± 118.4<0.00184.2 ± 50.6108.8 ± 71.0129.0 ± 96.9<0.001
HDL (mg/dL)54.3 ± 14.251.3 ± 13.151.2 ± 13.4<0.00164.3 ± 15.460.1 ± 14.657.8 ± 14.8<0.001

The data are expressed as numbers (percentages) for categorical variables and means ± standard deviations for continuous variables. The P values were tested using one-way analysis of variance for continuous variables and Pearson χ2 test or Fisher exact test for categorical variables.

Abbreviations: BMI, body mass index; VFA, Visceral fat area; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein.

Association between VFA/BMI and hearing loss

The AUROCs of VFA/BMI, VFA, and BMI for HL were 0.731 (95% CI, 0.722-0.739), 0.661 (95% CI, 0.652-0.670), and 0.530 (95% CI, 0.520-0.540) in men and 0.791 (95% CI, 0.782-0.799), 0.747 (95% CI, 0.737-0.756), and 0.583 (95% CI, 0.572-0.594) in women, respectively (Figure 1). The VFA/BMI had the highest AUROC and was the best predictor of HL (P <0.001). The sensitivity and specificity for predicting HL were 56.5% and 79.3% in men and 69.0% and 75.9% in women, respectively. According to univariate and multivariate analyses, the mean of the 4 hearing thresholds in both sexes increased as the VFA/BMI tertiles increased (Figure 2). In addition, a positive association of VFA/BMI with AHT was observed in the univariate and multivariate linear regression analyses (Table 2). The correlation coefficients between age and VFA/BMI were 0.594 in men and 0.796 in women (P < 0.001 in both sexes). However, VIFs for all explanatory variables, including age and VFA/BMI, were lesser than 10. These results show that age was positively associated with VFA/BMI, but multivariate models waived the risk of collinearity in both sexes.
Figure 1

Receiver operating characteristic curves of variable indices for the prediction of hearing loss in men (A) and women (B). Abbreviations: VFA, visceral fat area; BMI, body mass index.

Figure 2

Hearing thresholds according to visceral fat area/body mass index tertiles in men (A) and women (B). The multivariate analysis was adjusted for age, diabetes mellitus, hypertension, and chronic kidney disease (P < 0.05 for trends in all analyses). The data are expressed as mean and standard error values. Abbreviations: AHT, average hearing threshold; Low-Freq, low frequency; Mid-Freq, middle frequency; High-Freq, high frequency.

Table 2

Linear regression analyses of average hearing threshold according to visceral fat area/body mass index.

Independent variablesUnivariateMultivariate
Standardized β ± SEP-value*Standardized β ± SEP-value*VIF
Men
Age0.508 ± 0.010<0.0010.490 ± 0.013<0.0011.682
Diabetes mellitus0.084 ± 0.339<0.001-0.003 ± 0.2970.7601.035
Hypertension0.070 ± 0.262<0.0010.000 ± 0.2280.9741.031
eGFR-0.081 ± 0.008<0.0010.070 ± 0.007<0.0011.098
VFA/BMI0.347 ± 0.137<0.0010.066 ± 0.157<0.0011.576
Women
Age0.569 ± 0.011<0.0010.517 ± 0.018<0.0012.941
Diabetes mellitus0.159 ± 0.488<0.0010.021 ± 0.4190.0261.070
Hypertension0.185 ± 0.353<0.0010.025 ± 0.3080.0081.095
eGFR-0.118 ± 0.005<0.0010.033 ± 0.0040.0011.087
VFA/BMI0.479 ± 0.151<0.0010.062 ± 0.234<0.0012.761

*The dependent variable was average hearing threshold, and the multivariate analysis was adjusted for age, diabetes mellitus, hypertension, and eGFR.

Abbreviations: SE, standard error; VIF, variance inflation factor; eGFR, estimated glomerular filtration rate; VFA, visceral fat area; BMI, body mass index.

Men in the middle and high VFA/BMI tertiles had a 1.760 (95% CI, 1.403-2.209; P <0.001) and 5.746 (95% CI, 4.705-7.016; P <0.001) fold increased risk of HL compared to participants in the low VFA/BMI tertile according to the univariate logistic regression analysis (Table 3). Men in the middle and high VFA/BMI tertiles had a 1.630 (95% CI, 1.294-2.053; P <0.001) and 2.341 (95% CI, 1.869-2.933; P <0.001) fold increased risk of HL compared to those in the low VFA/BMI tertile according to the multivariate analysis. Women in the middle and high VFA/BMI tertiles had a 2.663 (95% CI, 1.976-3.590; P <0.001) and 11.976 (95% CI, 9.162-15.653; P <0.001) fold increased risk of HL compared to those in the low VFA/BMI tertile according to the univariate logistic regression analysis. Women in the middle and high VFA/BMI tertiles had a 2.317 (95% CI, 1.715-3.130; P <0.001) and 4.425 (95% CI, 3.277-5.977; P <0.001) fold increased risk of HL compared to those in the low VFA/BMI tertile according to multivariate analysis.
Table 3

Univariate and multivariate odds ratios for the hearing loss according to visceral fat area/body mass index tertiles.

MenWomen
Low tertileMiddle tertileHigh tertileLow tertileMiddle tertileHigh tertile
Univariate
Odds ratio1.01.7605.7461.02.66311.976
95% CIref1.403-2.2094.705-7.016ref1.976-3.5909.162-15.653
P-value<0.001<0.001<0.001<0.001
Multivariate
Odds ratio1.01.6302.3411.02.3174.425
95% CIref1.294-2.0531.869-2.933ref1.715-3.1303.277-5.977
P-value<0.001<0.001<0.001<0.001

The multivariate analysis was adjusted for age, diabetes mellitus, hypertension, and chronic kidney disease.

Abbreviations: CI, confidence interval.

Discussion

The VFA/BMI had the greatest AUROC among VFA, BMI, and VFA/BMI in both sexes in this study. In both univariate and multivariate analyses, VFA/BMI tertiles were associated with all 4 hearing thresholds (i.e., Low-Freq, Mid-Freq, High-Freq, and AHT). The 4 hearing thresholds were positively correlated with VFA/BMI as a continuous variable. The odds ratio for HL increased as the VFA/BMI tertile increased. According to these results, VFA/BMI was associated with HL in the Asian population. Obesity is an important risk factor for the development of hearing impairment in the general population 1-3. Adiponectin is inversely associated with obesity. VFA induces insulin resistance, overproduction of offensive adipokines (i.e., plasminogen activator inhibitor-1), and underproduction of defensive adipokines (i.e., adiponectin) 12. The change in adiponectin level with obesity plays a key role in the development of cardiometabolic complications or HL 12-15. The change in circulating adiponectin levels is greater among participants with high VFA than in high BMI or subcutaneous fat area 16. Circulating adiponectin levels in both sexes are increased by reduced VFA 17,18. Based on a study by Hwang et al., there was an association between plasma adiponectin levels and hearing thresholds 13. According to some studies, there was no association between BMI and hearing impairment, and that may be due to the inability to discriminate between VFA and subcutaneous fat area or muscle mass 5,6. Kim et al. investigated the association between VFA and hearing thresholds in 662 adults using computed tomography 8. They observed a significant association between the 2 variables in only 206 women. In addition, they analyzed the data using only linear regression analyses and divided the participants into only 2 threshold groups (low and high frequencies). To the best of our knowledge, there has been only one previous study to evaluate the association between VFA and hearing thresholds. The main technical advancement achieved in the current study was the method for VFA measurement. Although computed tomography and magnetic resonance imaging are the gold standard for assessing VFA, these are not proper methods in routine health-checkup settings. VFA measurement using BIA is simple, relatively accurate, and requires short imaging time. In present study, VFA measurements were normalized by BMI. The normalized VFA/BMI values had the highest AUROCs compared to the non-normalized VFA or BMI values. HL was defined as AHT >40 dB according to the serviceable hearing level. An association of VFA/BMI with all 4 variables and HL as a categorical variable was observed in both sexes. There were a few limitations in this study. Firstly, the study was limited by its retrospective nature. We were unable to evaluate ethnic differences, and establishing possible causality. Secondly, we did not evaluate the sensitive components of hearing impairments (i.e., speech discrimination or auditory brainstem response test). Thirdly, habitual parameters (i.e., alcohol consumption and smoking), and history of exposure to noise (i.e., occupational or explosive noise) were not evaluated in the present study. However, the impact of these limitations was reduced by the large sample size in this study. Further prospective analysis, including follow-up data and sensitive methods, is needed to evaluate a possible strong correlation between VFA/BMI and hearing impairment. In conclusion, VFA/BMI was associated with hearing impairment in the Asian population. Therefore, the participants with high VFA/BMI should be closely monitored for hearing impairment.
  18 in total

Review 1.  Adiponectin as a routine clinical biomarker.

Authors:  Ken Kishida; Tohru Funahashi; Iichiro Shimomura
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-08-20       Impact factor: 4.690

2.  Association of visceral fat area with chronic kidney disease and metabolic syndrome risk in the general population: analysis using multi-frequency bioimpedance.

Authors:  Seok Hui Kang; Kyu Hyang Cho; Jong Won Park; Kyung Woo Yoon; Jun Young Do
Journal:  Kidney Blood Press Res       Date:  2015-04-30       Impact factor: 2.687

3.  Association of plasma adiponectin levels with hearing thresholds in adults.

Authors:  Juen-Haur Hwang; Chuan-Jen Hsu; Tien-Chen Liu; Wei-Shiung Yang
Journal:  Clin Endocrinol (Oxf)       Date:  2011-11       Impact factor: 3.478

4.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

Authors:  K Hotta; T Funahashi; Y Arita; M Takahashi; M Matsuda; Y Okamoto; H Iwahashi; H Kuriyama; N Ouchi; K Maeda; M Nishida; S Kihara; N Sakai; T Nakajima; K Hasegawa; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Hanafusa; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

5.  A prospective study of cardiovascular risk factors and incident hearing loss in men.

Authors:  Josef Shargorodsky; Sharon G Curhan; Roland Eavey; Gary C Curhan
Journal:  Laryngoscope       Date:  2010-09       Impact factor: 3.325

6.  Contribution of adiponectin and its type 1 receptor to age-related hearing impairment.

Authors:  Chen-Chi Wu; Ching-Hui Tsai; Ying-Chang Lu; Hsiao-Chun Lin; Juen-Haur Hwang; Yin-Hung Lin; Wei-Shiung Yang; Pei-Jer Chen; Wei-Chih Liao; Yungling Leo Lee; Tien-Chen Liu; Chuan-Jen Hsu
Journal:  Neurobiol Aging       Date:  2015-03-05       Impact factor: 4.673

7.  Visceral adipose tissue is significantly associated with hearing thresholds in adult women.

Authors:  Tae Su Kim; Sung Won Park; Do Yeon Kim; Eon Bin Kim; Jong Woo Chung; Hong-Seob So
Journal:  Clin Endocrinol (Oxf)       Date:  2013-03-25       Impact factor: 3.478

8.  Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels.

Authors:  Theodore W K Ng; Gerald F Watts; P Hugh R Barrett; Kerry-Anne Rye; Dick C Chan
Journal:  Diabetes Care       Date:  2007-08-08       Impact factor: 19.112

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Adiponectin deficiency exacerbates age-related hearing impairment.

Authors:  T Tanigawa; R Shibata; N Ouchi; K Kondo; M Ishii; N Katahira; T Kambara; Y Inoue; R Takahashi; N Ikeda; S Kihara; H Ueda; T Murohara
Journal:  Cell Death Dis       Date:  2014-04-24       Impact factor: 8.469

View more
  3 in total

1.  The evaluation of cochlear functions in Familial Mediterranean Fever.

Authors:  Mehmet Akif Eryilmaz; Abitter Yucel; Erkan Cure; Davut Sakiz; Ahmet Koder; Adem Kucuk; Recep Tunc
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-29       Impact factor: 2.503

2.  The association between obesity, diet quality and hearing loss in older adults.

Authors:  Pauline H Croll; Trudy Voortman; Meike W Vernooij; Robert J Baatenburg de Jong; Frank R Lin; Fernando Rivadeneira; M Arfan Ikram; André Goedegebure
Journal:  Aging (Albany NY)       Date:  2019-01-04       Impact factor: 5.682

Review 3.  The Link between Gut Dysbiosis Caused by a High-Fat Diet and Hearing Loss.

Authors:  Dagmara Kociszewska; Jeffrey Chan; Peter R Thorne; Srdjan M Vlajkovic
Journal:  Int J Mol Sci       Date:  2021-12-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.